Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

被引：0
作者：
Laura Ordoñez-Boschetti
Roberto Rey
Ana Cruz
Arijit Sinha
Tracy Reynolds
Nadina Frider
Regina Alvarenga
机构：
[1] Consultorio de Medicina Especializada del Sector Privado,
[2] Instituto Argentino de Investigación Neurológica,undefined
[3] Centro de Investigaciones Médicas Hospital Nacional Alberto Sabogal Sologuren,undefined
[4] Novartis Healthcare Pvt. Ltd.,undefined
[5] Novartis Pharma AG,undefined
[6] Novartis LAtinAmerica and Canada Region,undefined
[7] MS Hospital Da Lagoa,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：636 / 636
相关论文
共 50 条
  • [1] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Ordonez-Boschetti, Laura
    Rey, Roberto
    Cruz, Ana
    Sinha, Arijit
    Reynolds, Tracy
    Frider, Nadina
    Alvarenga, Regina
    ADVANCES IN THERAPY, 2015, 32 (07) : 626 - 635
  • [2] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    Advances in Therapy, 2015, 32 : 626 - 635
  • [3] Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
    Doosti, Rozita
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Saleh, Shahrokh Karbalai
    Etemadifar, Masoud
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    Harirchian, Mohammad Hossein
    Siroos, Seyed Bahaadin
    Ayramloo, Hormoz
    Majdinasab, Nastaran
    Hojjati, Seyyed Mohammad Masood
    Asghari, Nabiollah
    Baghbanian, Seyed Mohammad
    Cheraghmakani, Hamed
    Abedini, Mahmoud
    Sedighi, Behnaz
    Abadi, Negar Mohseni Abbas
    Ghasemitabar, Maedeh
    Talebianpour, Sara
    Daylari, Tohid Babayi
    Dana, Vahid
    Noie, Neda Ghaleh
    Sahraian, Mohammad Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 263 - 274
  • [4] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Laroni, Alice
    Brogi, Davide
    Morra, Vincenzo Brescia
    Guidi, Leonello
    Pozzilli, Carlo
    Comi, Giancarlo
    Lugaresi, Alessandra
    Turrini, Renato
    Raimondi, Debora
    Uccelli, Antonio
    Mancardi, Giovanni Luigi
    NEUROLOGICAL SCIENCES, 2017, 38 (01) : 53 - 59
  • [5] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Alice Laroni
    Davide Brogi
    Vincenzo Brescia Morra
    Leonello Guidi
    Carlo Pozzilli
    Giancarlo Comi
    Alessandra Lugaresi
    Renato Turrini
    Debora Raimondi
    Antonio Uccelli
    Giovanni Luigi Mancardi
    Neurological Sciences, 2017, 38 : 53 - 59
  • [6] Safety and tolerability of fingolimod in relapsing-remitting multiple sclerosis: results from a large open-label clinical trial
    Laroni, A.
    Brogi, D.
    Morra, V. Brescia
    Guidi, L.
    Pozzilli, C.
    Comi, G.
    Lugaresi, A.
    Turrini, R.
    Raimondi, D.
    Uccelli, A.
    Mancardi, G. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 104 - 105
  • [7] Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN
    Bayas, Antonios
    Schuh, Katrin
    Baier, Monika
    Vormfelde, Stefan Viktor
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (05) : 378 - 388
  • [8] Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Gajofatto, Alberto
    Turatti, Marco
    Monaco, Salvatore
    Benedetti, Maria Donata
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 157 - 167
  • [9] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [10] QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Calabrese, P.
    Penner, I. -K.
    Carroll, C. A.
    Apfel, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S229 - S229
12345